KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Free Cash Flow (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Free Cash Flow for 9 consecutive years, with $41.3 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Free Cash Flow rose 2811.88% year-over-year to $41.3 million, compared with a TTM value of $13.6 million through Dec 2025, up 125.67%, and an annual FY2025 reading of $346.8 million, up 752.49% over the prior year.
  • Free Cash Flow was $41.3 million for Q2 2025 at Biocryst Pharmaceuticals, up from -$27.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $41.3 million in Q2 2025 and bottomed at -$53.9 million in Q1 2024.
  • Average Free Cash Flow over 3 years is -$13.5 million, with a median of -$13.3 million recorded in 2023.
  • The sharpest move saw Free Cash Flow dropped 13.1% in 2024, then soared 2811.88% in 2025.
  • Year by year, Free Cash Flow stood at -$7.3 million in 2023, then grew by 19.39% to -$5.9 million in 2024, then soared by 801.46% to $41.3 million in 2025.
  • Business Quant data shows Free Cash Flow for BCRX at $41.3 million in Q2 2025, -$27.7 million in Q1 2025, and -$5.9 million in Q4 2024.